Research progress of human amniotic membrane in the treatment of premature ovarian insufficiency

Abstract

Premature ovarian insufficiency (POI) is a clinical syndrome characterized by ovarian function decline before 40 years old. About 80% of POI are idiopathic. With the cancer diagnosis and treatment technology improved, the survivors are faced with the increased risk of POI. In recent years, stem cell therapy has obtained some achievements in the restoration of ovarian function at home and abroad. It has brought hope for the recovery of the endocrine function and fertility of POI patients. These stem cells include bone mesenchymal stem cells, umbilical cord mesenchymal stem cells, adipose mesenchymal stem cells, human amniotic epithelial cells (hAECs) and human amniotic mesenchymal stem cells (hAMSCs) and so on. Stem cells may provide microenvironment and inhibit follicle apoptosis by differentiating into granular cell cells or paracrine to restore damaged ovaries. This article mainly reviews research progresses about human amniotic membrane of POI. Key words: Amnion; Stem cells; Mesenchymal stem cells; Ovary; Female